Our Therapeutic
Areas of Focus
Powered by
TGF-ß science,
inspired by
patients
At Keros, our mission is to innovate therapies
that have the potential to shift the treatment
paradigm for a wide range of patients with
disorders that are linked to dysfunctional
signaling of the transforming growth
factor-beta (TGF-ß) family of proteins.
News
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition
December 9, 2024
Read More
Our Therapeutic
Advancing Novel Therapeutics With a Focus on Cellular Growth & Repair
The transforming growth factor-beta (TGF-β) superfamily is a group of regulatory proteins that is key to the growth, repair and maintenance of blood cells and a number of tissues. Leveraging our deep expertise in TGF-β science, we are focused on developing and commercializing novel therapeutics with the ability to modulate TGF-β signaling and unlock potentially disease-modifying benefits for patients in need.
Working at Keros is More Than
A Job - It's A Mission
What Drives Us
We take our mission personally.
We love our work.
It’s about the science.
We invest in our people.